Cutting-edge expertiseCutting-edge expertise

Cutting-edge biopharmaceuticals and diagnostics

Key figures

23 companies
2,165 employees, with 
1,700 estimated jobs specialized in research and development
$300 CDN million estimated in sales figures

Data compiled for the Québec City metropolitan region

As a hub for world research and expertise, the Québec City metropolitan region is an incubator for new and modern techniques that revolutionize vaccines, research and diagnostics.

Most biopharmaceutical companies in Québec City's metropolitan region are spinoffs from research conducted at the Université Laval. The technological platforms developed in its laboratories (genomics, proteomics, biocomputing, biochips and microchips) testify to the quality of its laboratory research.

Major medical breakthroughs in the region

Diseases such as bird flu or swine flu, colon cancer, diabetes, morbid obesity, cardiovascular metabolic syndrome and schizophrenia can be successfully diagnosed and treated, thanks to innovations from Québec. Some other major breakthroughs include:

  • Contribution of antio-estrogen to the treatment of breast cancer
  • Chemical castration with LhRH agonists (CDN $60 billion in global benefits)
  • Using DNA technology to identify microbes within 1 hour (rather than 48 hours)
  • Screening method for type 2 diabetes and cardiovascular disease

Leading researchers in biopharmaceuticals

  • Dr. Fernand Labrie
  • Dr. Michel G. Bergeron
  • Dr. Serge Rivest
  • Dr. Yves Fradet
  • Drs Auger et Germain

Diverse skills and expertise in biopharmaceuticals

Biopharmaceutical companies in the Québec City metropolitan region are distinguished in a number of areas. Each of these business sectors is comprised of leaders and SMEs (small- and medium-sized businesses):

Biopharma brochure

For more information

Vaccines and diagnostics - Quebec City, leading the way

Portrait of the biopharmaceutical industry in the Quebec City Region.

Produced by Québec International.

pdf_icon_32 Download the brochure

Share this page

You can share this page on :


Jean-MichelGarroLife Sciences

More details


Subscribe to our newsletter for interesting news and information.

Print this page